Cargando…

S204: SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, COMBINED WITH ANTI-PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: 18-MONTH RESULTS OF A PHASE 2 STUDY

Detalles Bibliográficos
Autores principales:	Valent, Jason, Liedtke, Michaela, Zonder, Jeffrey, Molina, Maria Angelica, Udata, Chandrasekhar, Ianus, Juliana, Tripptree, John, Catini, Julia, Quarta, C Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428285/ http://dx.doi.org/10.1097/01.HS9.0000967728.28017.25

Ejemplares similares

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

Compacted Area with Effective Links (CAEL) for Data Dissemination in VANETs
por: Kazi, Abdul Karim, et al.
Publicado: (2022)

Diagnostic and Therapeutic Considerations in Concurrent Plasma Cell Dyscrasia and Amyloidosis
por: Baljevic, Muhamed
Publicado: (2022)

Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy
por: Quarta, C. Cristina, et al.
Publicado: (2022)

Opium Dyscrasia
por: Moore,
Publicado: (1886)

Pus Dyscrasia
por: Barrett, W. C.
Publicado: (1881)

Quantitation of Monoclonal Plasma Cells in Bone Marrow Biopsies in Plasma Cell Dyscrasia
por: Markey, G. M., et al.
Publicado: (2003)

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
por: Roccaro, Aldo M, et al.
Publicado: (2008)

Post-Arsphenamine Blood Dyscrasias
por: Rajam, R. V., et al.
Publicado: (1938)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

AL Amyloidosis for Cardiologists: Awareness, Diagnosis, and Future Prospects: JACC: CardioOncology State-of-the-Art Review
por: Wechalekar, Ashutosh D., et al.
Publicado: (2022)

Telomerase activity in plasma cell dyscrasias
por: Xu, D, et al.
Publicado: (2001)

Basic Aural Dyscrasia and Vascular Deafness
Publicado: (1887)

Basic Aural Dyscrasia and Vascular Deafness
Publicado: (1886)

Ocular complications of plasma cell dyscrasias
por: Singh, Rohan Bir, et al.
Publicado: (2023)

GA101 (a Novel Anti-CD20 Monoclonal Antibody)-Induced Lichenoid Eruption
por: Bakkour, Waseem, et al.
Publicado: (2012)

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018)

Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression
por: Kim, Hyun Jung, et al.
Publicado: (2019)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

The 5-HT(1A) receptor biased agonists, NLX-204 and NLX-101, display ketamine-like RAAD and anti-TRD activities in rat CMS models
por: Papp, Mariusz, et al.
Publicado: (2023)

Crusted Scabies in Systemic Sclerosis with Plasma Cell Dyscrasia
por: Nikam, Balkrishna P., et al.
Publicado: (2018)

The Distribution and Nature of Sprue, with Notes on the Pathology of Intestinal Dyscrasias
por: Brown, W. Carnegie
Publicado: (1907)

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
por: Morelli, Eugenio, et al.
Publicado: (2020)

Pulmonary Vascular Disease Due to Plasma Cell Dyscrasia
por: Rajapreyar, Indranee, et al.
Publicado: (2020)

Imaging for Plasma Cell Dyscrasias: What, When, and How?
por: Guha, Amrita, et al.
Publicado: (2022)

Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma
por: Baz, Rachid C., et al.
Publicado: (2016)

Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents
por: Elmeliegy, Mohamed, et al.
Publicado: (2021)

The potential role of curcumin (diferuloylmethane) in plasma cell dyscrasias/paraproteinemia
por: Golombick, Terry, et al.
Publicado: (2008)

How I treat elderly patients with plasma cell dyscrasias
por: Gavriatopoulou, Maria, et al.
Publicado: (2018)

Mutational landscape reflects the biological continuum of plasma cell dyscrasias
por: Rossi, A, et al.
Publicado: (2017)

A case of plasma cell dyscrasia presenting as nonscarring alopecia
por: Nia, Benjamin, et al.
Publicado: (2021)

Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias
por: Janjetovic, Snjezana, et al.
Publicado: (2021)

Leptomeningeal isolated infiltration in plasma cell dyscrasia associated to HIV
por: Sprenger, Flávia, et al.
Publicado: (2022)

Impact of polypharmacy on inducing blood dyscrasias in clozapine treated patients
por: Shiri, M., et al.
Publicado: (2022)

COVID-19 vaccine immune response and plasma cell dyscrasia
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

The Role of the Gut Microbiome in Pathogenesis, Biology, and Treatment of Plasma Cell Dyscrasias
por: Jasiński, Marcin, et al.
Publicado: (2021)

S271: AN UPDATED FOLLOW-UP OF BRL-101, CRISPR-CAS9-MEDIATED GENE EDITING OF THE BCL11A ENHANCER FOR TRANSFUSION-DEPENDENT BETA-THALASSE
por: Fu, Bin, et al.
Publicado: (2023)

AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management
por: Witteles, Ronald M., et al.
Publicado: (2019)

T204. CLOZAPINE COMBINATION AND AUGMENTATION STRATEGIES IN PATIENTS WITH SCHIZOPHRENIA –RECOMMENDATIONS FROM AN INTERNATIONAL EXPERT SURVEY AMONG THE TREATMENT RESPONSE AND RESISTANCE IN PSYCHOSIS (TRRIP) WORKING GROUP
por: Wagner, Elias, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v19778alcfpqhqgaj0i89ig8j9